BioPhoenix Co

繁 簡
HOME / ABOUT US / History & Milestones

History & Milestones

2022
  • 三福生技成立新藥開發部門
    2022 2022 marked a milestone for SanFu Biotech with the establishment of the New Drug Development Division.
2023
  • 瑞格國際生技授權三福生技預防急性移植物抗宿主病(aGvHD)首創機制(First-in-class)新藥RGI-2001。
    2023.04.18 San Fu Biotech obtained the license for the first-in-class new drug RGI-2001 in preventing acute Graft-versus-Host Disease (aGvHD).
2025
  • 從三福化工子公司三福生技之新藥開發部門分割設立三福生醫公司。
    2025.03.12 BioPhoenix Co. was formally established as a spin-off from the New Drug Development Division of San Fu Biotech, a subsidiary of San Fu Chemical Co.
  • BPC2001-01預防急性移植物抗宿主疾病(aGvHD)中國臨床IIb期臨床試驗正式取得中國國家藥品監督管理局（NMPA）的新藥臨床試驗（IND）許可。
    2025.07.11 Obtained China NMPA IND approval for BPC2001-01 phase IIb trial in preventing acute Graft-versus-Host Disease (aGvHD).
  • 與美國約翰霍普金斯大學醫學院衍生之Up Therapeutics 簽署全球授權，引進治療卵巢癌First-in-Class新藥Up284之 Binding Term Sheet。
    2025.07.24 Signed a global licensing agreement with Up Therapeutics, a Johns Hopkins School of Medicine spin-out, to in-license Up284, a first-in-class therapy for several cancers.
  • BPC2001-01中國IIb期臨床試驗成功完成首例受試者給藥。
    2025.10.29 The first subject in the Phase IIb clinical trial of BPC2001-01 in China was successfully completed the first dose.